| Description | Inclacumab, a humanized monoclonal IgG4 antibody (Anti-Human Selectin P Recombinant Antibody), specifically binds to P-selectin with a dissociation constant (Kd) of 9.9 nM. It effectively prevents the interaction between P-selectin and P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide, with a half-maximal inhibitory concentration (IC50) of 1.9 µg/mL, and robustly impedes cell adhesion [1] [2] [3]. |
| In vitro | Inclacumab（0.4-40 μg/mL；5分钟）显著降低了P-Selectin与全血（WB）和分离的白细胞（I-WBC）的流动性粘附，并对分离的白细胞表现出更加强烈的效果[1]。Inclacumab对P-Selectin具有很高的结合亲和力，Kd值为9.9 nM[2]。Inclacumab抑制PSGL-1模拟肽与P-Selectin的结合，IC50值为1.9 µg/mL[2]；阻断PSGL-1表达细胞与固定P-Selectin的粘附，IC50值为430 ng/mL[2]。Inclacumab（0-100 μg/mL；5分钟）剂量依赖性地抑制由血栓素受体激活肽（TRAP）诱导的血小板-白细胞聚集物（PLA）水平，IC50值为1.4 μg/mL[3]。 |
| In vivo | Inclacumab，在给予黑猩猩一次性皮下注射4 mg/kg剂量后，能降低TRAP和ADP诱导的PLA水平[3]。以2-50 mg/kg剂量，经静脉途径每周一次连续注射13周，亦能抑制TRAP诱导的PLA水平[3]。 |
| Synonyms | Anti-Human selectin P Recombinant Antibody |
| molecular weight | N/A |
| CAS | 1256258-86-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years |